Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2008 Jun;28(6):1031-3.
doi: 10.1161/ATVBAHA.108.164830.

The homocysteine paradox

Roman N Rodionov, Steven R Lentz
Editorial

The homocysteine paradox

Roman N Rodionov et al. Arterioscler Thromb Vasc Biol. 2008 Jun.
No abstract available

PubMed Disclaimer

Figures

None
Possible mechanistic relationships between renal dysfunction and vascular disease. Impaired renal function causes elevation of homocysteine and asymmetric dimethylarginine (ADMA), both of which are associated with an increased risk of vascular disease. Homocysteine may be a direct mediator of vascular disease or a marker of ADMA or other etiological factors related to renal dysfunction.
See this image and copyright information in PMC

Comment in

  • Homocysteine is not so paradoxical.
    Klevay LM. Klevay LM. Arterioscler Thromb Vasc Biol. 2008 Oct;28(10):e160; author reply e161. doi: 10.1161/ATVBAHA.108.172072. Arterioscler Thromb Vasc Biol. 2008. PMID: 18799792 No abstract available.

Comment on

References

    1. Homocysteine Studies Collaboration Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015–22. - PubMed
    1. den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost. 2005;3:292–9. - PubMed
    1. Dayal S, Lentz SR. Role of redox reactions in the vascular phenotype of hyperhomocysteinemic animals. Antioxid Redox Signal. 2007;9:1899–909. - PubMed
    1. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565–75. - PubMed
    1. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J., Jr Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567–77. - PubMed